Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYTH-1 anakinra for virus-negative myocarditis
2018-003472-13Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocarditis and autoimmune myocarditis comparing Anakinra plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Improvement in left ventricular ejection fraction at 2 months. Started Jun 2021; status: active.
02
Drugs
anakinra
03
Conditions
myocarditisautoimmune myocarditis
Beyond the preview
Go deeper on 2018-003472-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003472-13.